340042-24-2Relevant academic research and scientific papers
Targeting the ribose and phosphate binding site of p38 mitogen-activated protein (MAP) kinase: Synthesis and biological testing of 2-alkylsulfanyl-, 4(5)-aryl-, 5(4)-heteroaryl-substituted imidazoles
Koch, Pierre,B?uerlein, Christiane,Jank, Hartmut,Laufer, Stefan
supporting information; experimental part, p. 5630 - 5640 (2009/09/06)
Three series of substituted 2-alkylsulfanyl-4-(4-fluorophenyl)imidazoles, 5-pyridinyl-, 1-methyl-5-pyridinyl-, and 5-(2-aminopyridin-4-yl)-imidazoles, were prepared and tested for their ability to inhibit p38 MAP kinase and TNF-α release. These compounds
Towards the improvement of the synthesis of novel 4(5)-aryl-5(4)- heteroaryl-2-thio-substituted imidazoles and their p38 MAP kinase inhibitory activity
Laufer, Stefan,Koch, Pierre
supporting information; experimental part, p. 437 - 439 (2008/10/09)
A series of 2-alkylsulfanyl-4-(4-fluorophenyl)-5-(2-aminopyridin-4-yl)- substituted imidazoles was prepared and interaction possibilities of the 2-thioether moiety with phosphate/ribose binding pockets of p38 MAP kinase were investigated. Introduction of the alkyl/benzyl amino function at the pyridine moiety was carried out via nucleophilic substitution or via palladium catalyzed aryl-C-N-bond formation. The Royal Society of Chemistry 2008.
Imidazopyrimidines, potent inhibitors of p38 MAP kinase
Rupert, Kenneth C.,Henry, James R.,Dodd, John H.,Wadsworth, Scott A.,Cavender, Druie E.,Olini, Gilbert C.,Fahmy, Bohumila,Siekierka, John J.
, p. 347 - 350 (2007/10/03)
The MAP kinase p38 is implicated in the release of the pro-inflammatory cytokines TNF-α and IL-1β. Inhibition of cytokine release may be a useful treatment for inflammatory conditions such as rheumatoid arthritis and Crohn's disease. A novel series of imidazopyrimidines have been discovered that potently inhibit p38 and suppress the production of TNF-α in vivo.
